Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Precision medicine and public health interventions: tuberculosis as a model?

Temesgen Z, Cirillo DM, Raviglione MC.

Lancet Public Health. 2019 Aug;4(8):e374. doi: 10.1016/S2468-2667(19)30130-6. No abstract available.

2.

Dolutegravir plus lamivudine dual therapy - a new option for initial antiretroviral therapy.

Fida M, Rizza SA, Temesgen Z.

Drugs Today (Barc). 2019 May;55(5):297-304. doi: 10.1358/dot.2019.55.5.2962947. Review.

PMID:
31131840
3.

Tuberculosis in Children.

Holmberg PJ, Temesgen Z, Banerjee R.

Pediatr Rev. 2019 Apr;40(4):168-178. doi: 10.1542/pir.2018-0093. No abstract available. Erratum in: Pediatr Rev. 2019 Jun;40(6):318.

PMID:
30936398
4.

Building a tuberculosis-free world: The Lancet Commission on tuberculosis.

Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, Chin DP, Churchyard G, Cox H, Ditiu L, Dybul M, Farrar J, Fauci AS, Fekadu E, Fujiwara PI, Hallett TB, Hanson CL, Harrington M, Herbert N, Hopewell PC, Ikeda C, Jamison DT, Khan AJ, Koek I, Krishnan N, Motsoaledi A, Pai M, Raviglione MC, Sharman A, Small PM, Swaminathan S, Temesgen Z, Vassall A, Venkatesan N, van Weezenbeek K, Yamey G, Agins BD, Alexandru S, Andrews JR, Beyeler N, Bivol S, Brigden G, Cattamanchi A, Cazabon D, Crudu V, Daftary A, Dewan P, Doepel LK, Eisinger RW, Fan V, Fewer S, Furin J, Goldhaber-Fiebert JD, Gomez GB, Graham SM, Gupta D, Kamene M, Khaparde S, Mailu EW, Masini EO, McHugh L, Mitchell E, Moon S, Osberg M, Pande T, Prince L, Rade K, Rao R, Remme M, Seddon JA, Selwyn C, Shete P, Sachdeva KS, Stallworthy G, Vesga JF, Vilc V, Goosby EP.

Lancet. 2019 Mar 30;393(10178):1331-1384. doi: 10.1016/S0140-6736(19)30024-8. Epub 2019 Mar 20. Review. No abstract available.

PMID:
30904263
5.

Ibalizumab for the treatment of multidrug-resistant HIV-1 infection.

Rizza SA, Bhatia R, Zeuli J, Temesgen Z.

Drugs Today (Barc). 2019 Jan;55(1):25-34. doi: 10.1358/dot.2019.55.1.2895651.

PMID:
30740610
6.

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection in adults.

Nehra V, Rizza SA, Temesgen Z.

Drugs Today (Barc). 2018 Jul;54(7):407-421. doi: 10.1358/dot.2018.54.7.2828188. Review.

PMID:
30090878
7.

Screening for tuberculosis in migrants and visitors from high-incidence settings: present and future perspectives.

Dobler CC, Fox GJ, Douglas P, Viney KA, Ahmad Khan F, Temesgen Z, Marais BJ.

Eur Respir J. 2018 Jul 11;52(1). pii: 1800591. doi: 10.1183/13993003.00591-2018. Print 2018 Jul. Review.

PMID:
29794133
8.

Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children.

Rizza SA, Nehra V, Temesgen Z.

Drugs Today (Barc). 2017 Aug;53(8):447-451. doi: 10.1358/dot.2017.53.8.2687529.

PMID:
29119149
9.

Babesia microti infection and hemophagocytic lymphohistiocytosis in an immunocompetent patient.

Go SA, Phuoc VH, Eichenberg SE, Temesgen Z, Beckman TJ.

Int J Infect Dis. 2017 Dec;65:72-74. doi: 10.1016/j.ijid.2017.09.026. Epub 2017 Oct 6.

10.

Evaluating clinicians' user experience and acceptability of LearnTB, a smartphone application for tuberculosis in India.

Pande T, Saravu K, Temesgen Z, Seyoum A, Rai S, Rao R, Mahadev D, Pai M, Gagnon MP.

Mhealth. 2017 Jul 27;3:30. doi: 10.21037/mhealth.2017.07.01. eCollection 2017.

11.

Tuberculosis control, and the where and why of artificial intelligence.

Doshi R, Falzon D, Thomas BV, Temesgen Z, Sadasivan L, Migliori GB, Raviglione M.

ERJ Open Res. 2017 Jun 21;3(2). pii: 00056-2017. doi: 10.1183/23120541.00056-2017. eCollection 2017 Apr. Review.

12.

Sofosbuvir/velpatasvir fixed-dose combination for the treatment of chronic hepatitis C virus infection.

Nehra V, Rizza SA, Temesgen Z.

Drugs Today (Barc). 2017 Mar;53(3):177-189. doi: 10.1358/dot.2017.53.3.2604176. Review.

PMID:
28447075
13.

Implementation and Evaluation of a Blended Learning Course on Tuberculosis for Front-Line Health Care Professionals.

Manyazewal T, Marinucci F, Belay G, Tesfaye A, Kebede A, Tadesse Y, Lehman S, Temesgen Z.

Am J Clin Pathol. 2017 Mar 1;147(3):285-291. doi: 10.1093/ajcp/aqx002.

PMID:
28395055
15.

Tenofovir alafenamide fumarate for the treatment of HIV infection.

Sampath R, Zeuli J, Rizza S, Temesgen Z.

Drugs Today (Barc). 2016 Nov;52(11):617-625. doi: 10.1358/dot.2016.52.11.2546852. Review.

PMID:
28112280
16.

Clinical Reasoning: A 73-year-old man with sarcoidosis and multifocal ischemic strokes.

Pichler M, Klaas J, Temesgen Z, Kantarci O.

Neurology. 2016 Sep 20;87(12):e119-23. doi: 10.1212/WNL.0000000000003128. No abstract available.

17.

Digital health for the End TB Strategy: developing priority products and making them work.

Falzon D, Timimi H, Kurosinski P, Migliori GB, Van Gemert W, Denkinger C, Isaacs C, Story A, Garfein RS, do Valle Bastos LG, Yassin MA, Rusovich V, Skrahina A, Van Hoi L, Broger T, Abubakar I, Hayward A, Thomas BV, Temesgen Z, Quraishi S, von Delft D, Jaramillo E, Weyer K, Raviglione MC.

Eur Respir J. 2016 Jul;48(1):29-45. doi: 10.1183/13993003.00424-2016. Epub 2016 May 26.

18.

Twenty years of human immunodeficiency virus care at the Mayo Clinic: Past, present and future.

Cummins NW, Badley AD, Kasten MJ, Sampath R, Temesgen Z, Whitaker JA, Wilson JW, Yao JD, Zeuli J, Rizza SA.

World J Virol. 2016 May 12;5(2):63-7. doi: 10.5501/wjv.v5.i2.63. Review.

19.

Poststernotomy Osteomyelitis Presenting with Severe Sepsis and Rhabdomyolysis.

Tan EM, Lyle M, Cawcutt K, Temesgen Z.

Case Rep Med. 2016;2016:4507012. doi: 10.1155/2016/4507012. Epub 2016 Apr 10.

20.

Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection.

Nehra V, Tan EM, Rizza SA, Temesgen Z.

Drugs Today (Barc). 2016 Feb;52(2):111-7. doi: 10.1358/dot.2016.52.2.2449840. Review.

PMID:
27092340
21.

Isavuconazonium sulfate for the treatment of fungal infection.

Walker RC, Zeuli JD, Temesgen Z.

Drugs Today (Barc). 2016 Jan;52(1):7-16. doi: 10.1358/dot.2016.52.1.2404002. Review.

PMID:
26937491
22.

Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection.

Zeuli JD, Adie SK, Rizza SA, Temesgen Z.

Drugs Today (Barc). 2015 Nov;51(11):629-43. doi: 10.1358/dot.2015.51.11.2414528. Review.

PMID:
26744738
23.

Daclatasvir for the treatment of chronic hepatitis C virus infection.

Temesgen Z, Rizza SA.

Drugs Today (Barc). 2015 May;51(5):277-88. doi: 10.1358/dot.2015.51.5.2312449. Review.

PMID:
26097901
24.

Sofosbuvir for the treatment of chronic hepatitis C virus infection.

Temesgen Z, Talwani R, Rizza SA.

Drugs Today (Barc). 2014 Jun;50(6):421-34. doi: 10.1358/dot.2014.50.6.2141371. Review.

PMID:
24983590
25.

Dolutegravir, an HIV integrase inhibitor for the treatment of HIV infection.

Temesgen Z, Talwani R, Rizza SA.

Drugs Today (Barc). 2014 Jan;50(1):7-14. doi: 10.1358/dot.2014.50.1.2097790.

PMID:
24524102
26.

Simeprevir: a macrocyclic HCV protease inhibitor.

Talwani R, Heil EL, Gilliam BL, Temesgen Z.

Drugs Today (Barc). 2013 Dec;49(12):769-79. doi: 10.1358/dot.2013.49.12.2067249.

PMID:
24524095
27.

Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41.

Cummins NW, Neuhaus J, Sainski AM, Strausbauch MA, Wettstein PJ, Lewin SR, Plana M, Rizza SA, Temesgen Z, Touloumi G, Freiberg M, Neaton J, Badley AD; INSIGHT SMART Study Group.

AIDS Res Hum Retroviruses. 2014 May;30(5):476-9. doi: 10.1089/AID.2013.0243. Epub 2014 Feb 14.

28.

Cobicistat, a pharmacoenhancer for HIV treatments.

Temesgen Z.

Drugs Today (Barc). 2013 Apr;49(4):233-7. doi: 10.1358/dot.2013.49.4.1947288.

PMID:
23616950
29.

Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection.

Temesgen Z.

Drugs Today (Barc). 2012 Dec;48(12):765-71. doi: 10.1358/dot.2012.48.12.1895682. Review.

PMID:
23243633
30.

HIV screening in the health care setting: status, barriers, and potential solutions.

Rizza SA, MacGowan RJ, Purcell DW, Branson BM, Temesgen Z.

Mayo Clin Proc. 2012 Sep;87(9):915-24. doi: 10.1016/j.mayocp.2012.06.021.

31.

Current status of treatment for chronic hepatitis C virus infection.

Talwani R, Gilliam BL, Rizza SA, Nehra V, Temesgen Z.

Drugs Today (Barc). 2012 Mar;48(3):219-31. doi: 10.1358/dot.2012.48.3.1740457. Review.

PMID:
22462041
32.

Telaprevir: looking for a sustained virologic response in hepatitis C virus infection.

Nehra V, Rizza SA, Talwani R, Temesgen Z.

Drugs Today (Barc). 2011 Nov;47(11):829-37. doi: 10.1358/dot.2011.47.11.1678339. Review.

PMID:
22146226
33.

HIV in Africa: Challenges and Directions for the Next Decade.

Gilliam BL, Patel D, Talwani R, Temesgen Z.

Curr Infect Dis Rep. 2012 Feb;14(1):91-101. doi: 10.1007/s11908-011-0230-8.

PMID:
22143960
34.

Boceprevir.

Rizza SA, Talwani R, Nehra V, Temesgen Z.

Drugs Today (Barc). 2011 Oct;47(10):743-51. doi: 10.1358/dot.2011.47.10.1656503. Review.

PMID:
22076489
35.

Introduction to the Symposium on Antimicrobial Therapy.

Temesgen Z.

Mayo Clin Proc. 2011 Feb;86(2):86-7. doi: 10.4065/mcp.2011.0002. No abstract available.

36.

Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations.

Soliman EZ, Lundgren JD, Roediger MP, Duprez DA, Temesgen Z, Bickel M, Shlay JC, Somboonwit C, Reiss P, Stein JH, Neaton JD; INSIGHT SMART Study Group.

AIDS. 2011 Jan 28;25(3):367-77. doi: 10.1097/QAD.0b013e328341dcc0.

37.

HIV lumbosacral radiculoplexus neuropathy mimicking lymphoma: diffuse infiltrative lymphocytosis syndrome (DILS) restricted to nerve?

Chahin N, Temesgen Z, Kurtin PJ, Spinner RJ, Dyck PJ.

Muscle Nerve. 2010 Feb;41(2):276-82. doi: 10.1002/mus.21507.

38.

Micafungin - the newest echinocandin.

Temesgen Z, Barreto J, Vento S.

Drugs Today (Barc). 2009 Jun;45(6):469-78. Review.

PMID:
19856528
39.
40.

Lung infections after cancer chemotherapy.

Vento S, Cainelli F, Temesgen Z.

Lancet Oncol. 2008 Oct;9(10):982-92. doi: 10.1016/S1470-2045(08)70255-9. Review.

PMID:
19071255
41.

Using natural language processing for identification of pneumonia cases from clinical records of patients with serologically proven influenza.

Wahner-Roedler DL, Welsh GA, Trusko BE, Froehling DA, Temesgen Z, Elkin PL.

AMIA Annu Symp Proc. 2008 Nov 6:1165.

PMID:
18998814
42.

Perspectives in therapy for hepatitis C.

Vento S, Cainelli F, Temesgen Z.

Expert Opin Investig Drugs. 2008 Nov;17(11):1635-9. doi: 10.1517/13543784.17.11.1635 . Review.

PMID:
18922100
43.

Raltegravir: first in class HIV integrase inhibitor.

Temesgen Z, Siraj DS.

Ther Clin Risk Manag. 2008 Apr;4(2):493-500.

44.

Screening and assessment of coronary heart disease in HIV-infected patients.

Hsue PY, Squires K, Bolger AF, Capili B, Mensah GA, Temesgen Z, Wanke CA, Wohl DA; Working Group 4.

Circulation. 2008 Jul 8;118(2):e41-7. doi: 10.1161/CIRCULATIONAHA.107.189626. Epub 2008 Jun 19. No abstract available.

PMID:
18566317
45.

Biosurveillance evaluation of SNOMED CT's terminology (BEST Trial): coverage of chief complaints.

Elkin PL, Brown SH, Balas A, Temesgen Z, Wahner-Roedler D, Froehling D, Liebow M, Trusko B, Rosenbloom ST, Poland G.

Stud Health Technol Inform. 2008;136:797-802.

PMID:
18487829
46.

Advances in antiretroviral therapy.

Temesgen Z.

Drug News Perspect. 2008 Mar;21(2):125-31.

PMID:
18389104
47.

Etravirine.

Knoll BM, Vento S, Temesgen Z.

Drugs Today (Barc). 2008 Jan;44(1):23-33. doi: 10.1358/dot.2008.44.1.1152213. Review.

PMID:
18301801
48.

Maraviroc.

Fadel H, Temesgen Z.

Drugs Today (Barc). 2007 Nov;43(11):749-58. doi: 10.1358/dot.2007.43.11.1131763. Review.

PMID:
18174962
49.

Current status of HIV infection: a review for non-HIV-treating physicians.

Knoll B, Lassmann B, Temesgen Z.

Int J Dermatol. 2007 Dec;46(12):1219-28. doi: 10.1111/j.1365-4632.2007.03520.x. Review.

PMID:
18173512
50.

Antiretroviral drugs.

Warnke D, Barreto J, Temesgen Z.

J Clin Pharmacol. 2007 Dec;47(12):1570-9. Review.

PMID:
18048575

Supplemental Content

Loading ...
Support Center